Novavax Completes Asset Acquisition/Disposition

TL;DR

Novavax just did a deal involving assets, details TBD.

AI Summary

On December 30, 2024, Novavax, Inc. filed an 8-K report indicating the completion of an acquisition or disposition of assets. The filing does not specify the nature of the transaction, the counterparty, or any financial details related to the asset change.

Why It Matters

This filing signals a change in Novavax's asset portfolio, which could impact its operational capacity, financial structure, or strategic direction.

Risk Assessment

Risk Level: medium — The lack of specific details in this 8-K filing creates uncertainty about the nature and impact of the asset transaction.

Key Players & Entities

• Novavax, Inc. (company) — Registrant
• December 30, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se
• $200 million — tal purchase price for the Facility was $200 million and the assumption by the Purchaser of
• $180 m — he Purchaser received a cash payment of $180 million, net of the initial payment of $1
• $10 million — million, net of the initial payment of $10 million made in September 2024 and $10 million
• $2 — mpany was also reimbursed approximately $2. 6 million, subject to adjustments, for

Filing Documents

• tm2432218d1_8k.htm (8-K) — 26KB
• 0001104659-24-132569.txt ( ) — 194KB
• nvax-20241230.xsd (EX-101.SCH) — 3KB
• nvax-20241230_lab.xml (EX-101.LAB) — 33KB
• nvax-20241230_pre.xml (EX-101.PRE) — 22KB
• tm2432218d1_8k_htm.xml (XML) — 3KB

01 Completion of Acquisition or Disposition of Assets

Item 2.01 Completion of Acquisition or Disposition of Assets. On December 30, 2024, Novavax CZ a.s. (the "Seller"), an indirect, a wholly owned subsidiary of Novavax Inc. (the "Company"), completed the previously-announced sale of the Company's biologics manufacturing campus located at Bohumil, Jevany, Czech Republic (the "Facility") to Novo Nordisk Production Czech s.r.o. (the "Purchaser"), pursuant to an asset purchase agreement, dated as of December 3, 2024 (the "Asset Purchase Agreement"), by and among the Seller, the Company, the Purchaser and Novo Nordisk A/S. Pursuant to the Asset Purchase Agreement, the Seller sold, transferred and assigned to the Purchaser: (i) properties owned by the Seller registered on folio No. 894 maintained by the Cadastral Office for Central Bohemian Region, Detached Cadastral Office Prague-East, for the cadastral area Jevany, comprising land in the settlement known as Bohumil, as well as certain moveable assets and equipment located at the manufacturing facility (the "Transferred Assets"); (ii) contracts related to the operation and management of the Transferred Assets (the "Transferred Contracts"); and (iii) certain employees currently providing services related to the Transferred Assets (the "Transferred Employees"). The total purchase price for the Facility was $200 million and the assumption by the Purchaser of liabilities (on a look-forward basis) pertaining to the Transferred Assets, Transferred Contracts and Transferred Employees. On the closing date, the Purchaser received a cash payment of $180 million, net of the initial payment of $10 million made in September 2024 and $10 million placed in an escrow account to be released to the Seller on the date which is 12 months following the closing date (subject to adjustment for any claims the Purchaser may have against the Seller under the Asset Purchase Agreement). Pursuant to the terms of the Asset Purchase Agreement, the Company was also reimbursed approximately $2. 6 millio

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Novavax, Inc. Date: December 30, 2024 By: /s/ Mark J. Casey Name: Mark J. Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary 2

View Full Filing

View this 8-K filing on SEC EDGAR